Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study

被引：2

作者：

Nasu, Izumi ^{[1
,2
]}

Kondo, Masahiro ^{[3
]}

Uozumi, Ryuji ^{[4
]}

Takada, Shinya ^{[5
]}

Nawata, Shuichi ^{[6
]}

Iihara, Hirotoshi ^{[7
]}

Okumura, Yohei ^{[8
]}

Takemoto, Masashi ^{[3
]}

Mino, Kozo

Sasaki, Tadanori ^{[6
]}

Hirose, Chiemi ^{[7
]}

Aomori, Tohru ^{[8
]}

Shimano, Rena ^{[2
]}

Maeno, Ken ^{[9
]}

Oizumi, Satoshi ^{[10
]}

Kusumoto, Sojiro ^{[11
]}

Ohno, Yasushi ^{[12
]}

Ikemura, Shinnosuke ^{[13
]}

Takai, Daiya ^{[14
]}

Hara, Azusa ^{[15
]}

Kawazoe, Hitoshi ^{[1
]}

Nakamura, Tomonori ^{[1
]}

机构：

[1] Keio Univ, Div Pharmaceut Care Sci, Grad Sch Pharmaceut Sci, 1-5-30 Shibakoen,Minato Ku, Tokyo 1058512, Japan

[2] Toranomon Gen Hosp, Dept Pharm, 2-2-2 Toranomon,Minato Ku, Tokyo 1058470, Japan

[3] Nagoya City Univ Hosp, Dept Pharm, 1-Kawasumi, Mizuho Cho,Miskuho Ku, Nagoya, Aichi 4678602, Japan

[4] Tokyo Inst Technol, Dept Ind Engn & Econ, 2-12-1 Ookayama,Meguro Ku, Tokyo 1528552, Japan

[5] Natl Hosp Org Hokkaido Canc Ctr, Dept Pharm, 4-2-3-54 Kikusui,Shiroishi Ku, Sapporo 0030804, Japan

[6] Showa Univ, Dept Hosp Pharmaceut, Sch Pharm, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo 1428666, Japan

[7] Gifu Univ Hosp, Dept Pharm, 1-1 Yanagido, Gifu, Gifu 5011194, Japan

[8] Keio Univ Hosp, Dept Pharm, 35 Shinanomachi,Shinjuku Ku, Tokyo 1608582, Japan

[9] Nagoya City Univ, Dept Resp Med Allergy & Clin Immunol, Grad Sch Med Sci, 1-Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya, Aichi 4678602, Japan

[10] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, 4-2-3-54 Kikusui,Shiroishi Ku, Sapporo 0030804, Japan

[11] Showa Univ, Resp Med & Allergol, Sch Med, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo 1428666, Japan

[12] Gifu Univ, Dept Cardiol & Resp Med, Grad Sch Med, 1-1 Yanagido, Gifu 5011194, Japan

[13] Keio Univ, Dept Med, Div Pulm Med, Sch Med, 35 Shinanomachi,Shinjuku Ku, Tokyo 1608582, Japan

[14] Toranomon Gen Hosp, Dept Resp Med, 2-2-2 Toranomon,Minato Ku, Tokyo 1058470, Japan

[15] Keio Univ, Div Drug Dev & Regulatory Sci, Fac Pharm, 1-5-30 Shibakoen,Minato Ku, Tokyo 1058512, Japan

来源：

JOURNAL OF CANCER | 2023年 / 14卷 / 05期

关键词：

pembrolizumab; atezolizumab; immune checkpoint inhibitors; baseline medications; prognostic model; non-small-cell lung cancer; ADVERSE EVENTS; OUTCOMES; PEMBROLIZUMAB; ASSOCIATION; BIOMARKERS; SURVIVAL; EFFICACY;

D O I：

10.7150/jca.80517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Association between baseline medications plus neutrophil-to-lymphocyte ratio (NLR) and the effectiveness of immune checkpoint inhibitor (ICI) plus platinum doublet remains unknown, despite several reported prognostic models. We used real-world data to investigate whether baseline medications plus NLR predict survival outcomes in patients with advanced non-small-cell lung cancer (NSCLC) receiving ICI plus platinum doublet. Methods: This multicenter, retrospective, observational study conducted in Japan between December 2018 and March 2021 used real-world data of consecutive patients with advanced NSCLC who received ICI (pembrolizumab or atezolizumab) plus platinum doublet as first-line treatment. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The prognostic score for baseline medications plus NLR was weighted by regression beta coefficients and used to categorize patients into good, intermediate, and poor prognoses groups. In addition, time-dependent receiver operating characteristic curve analyses and univariable and multivariable Cox proportional hazards models were constructed. Results: Overall, 241 patients were included. Poor prognosis was significantly associated with worse PFS (hazard ratio [HR]: 1.78; 95% confidence interval [CI]: 1.08-2.94; P = 0.025) and OS (HR: 3.59; 95% CI: 2.05- 6.28; P < 0.001) than good prognosis. Harrell's C-index for this prognostic model was 0.648.Conclusions: Baseline medication plus NLR could predict progressively worse survival outcomes in patients with advanced NSCLC receiving ICI plus platinum doublet and could be used as a prognostic index for poor outcomes.

引用

页码：676 / 688

页数：13

共 34 条

[1] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[2] Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis [J].

Benedict Sacdalan, Danielle ;

Anne Lucero, Josephine ;

Lee Sacdalan, Dennis .

ONCOTARGETS AND THERAPY, 2018, 11 :955-965

[3] Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy [J].

Buti, Sebastiano ;

Bersanelli, Melissa ;

Perrone, Fabiana ;

Bracarda, Sergio ;

Di Maio, Massimo ;

Giusti, Raffaele ;

Nigro, Olga ;

Cortinovis, Diego L. ;

Aerts, Joachim G. J. V. ;

Guaitoli, Giorgia ;

Barbieri, Fausto ;

Ferrara, Miriam G. ;

Bria, Emilio ;

Grossi, Francesco ;

Bareggi, Claudia ;

Berardi, Rossana ;

Torniai, Mariangela ;

Cantini, Luca ;

Sforza, Vincenzo ;

Genova, Carlo ;

Chiari, Rita ;

Rocco, Danilo ;

Della Gravara, Luigi ;

Gori, Stefania ;

De Tursi, Michele ;

Di Marino, Pietro ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Filetti, Marco ;

Citarella, Fabrizio ;

Russano, Marco ;

Mazzoni, Francesca ;

Garassino, Marina C. ;

De Toma, Alessandro ;

Signorelli, Diego ;

Gelibter, Alain ;

Siringo, Marco ;

Follador, Alessandro ;

Bisonni, Renato ;

Tuzi, Alessandro ;

Minuti, Gabriele ;

Landi, Lorenza ;

Ricciardi, Serena ;

Migliorino, Maria R. ;

Tabbo, Fabrizio ;

Olmetto, Emanuela ;

Metro, Giulio ;

Adamo, Vincenzo ;

Russo, Alessandro ;

Spinelli, Gian P. .

EUROPEAN JOURNAL OF CANCER, 2021, 150 :224-231

[4] Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index [J].

Buti, Sebastiano ;

Bersanelli, Melissa ;

Perrone, Fabiana ;

Tiseo, Marcello ;

Tucci, Marco ;

Adamo, Vincenzo ;

Stucci, Luigia S. ;

Russo, Alessandro ;

Tanda, Enrica T. ;

Spagnolo, Francesco ;

Rastelli, Francesca ;

Pergolesi, Federica ;

Santini, Daniele ;

Russano, Marco ;

Anesi, Cecilia ;

Giusti, Raffaele ;

Filetti, Marco ;

Marchetti, Paolo ;

Botticelli, Andrea ;

Gelibter, Alain ;

Occhipinti, Mario Alberto ;

Ferrari, Marco ;

Vitale, Maria Giuseppa ;

Nicolardi, Linda ;

Chiari, Rita ;

Rijavec, Erika ;

Nigro, Olga ;

Tuzi, Alessandro ;

De Tursi, Michele ;

Di Marino, Pietro ;

Conforti, Fabio ;

Queirolo, Paola ;

Bracarda, Sergio ;

Macrini, Serena ;

Gori, Stefania ;

Zoratto, Federica ;

Veltri, Enzo ;

Di Cocco, Barbara ;

Mallardo, Domenico ;

Vitale, Maria Grazia ;

Santoni, Matteo ;

Patruno, Leonardo ;

Porzio, Giampiero ;

Ficorella, Corrado ;

Pinato, David J. ;

Ascierto, Paolo A. ;

Cortellini, Alessio .

EUROPEAN JOURNAL OF CANCER, 2021, 142 :18-28

[5]

Chalabi M, 2020, ANN ONCOL, V31, P525, DOI [10.1016/j.annoc.2020.01.006, 10.1016/j.annonc.2020.01.006]

[6] Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors [J].

Chen, Shixue ;

Li, Ruixin ;

Zhang, Zhibo ;

Huang, Ziwei ;

Cui, Pengfei ;

Jia, Wangping ;

Zhang, Sujie ;

Tao, Haitao ;

Wang, Lijie ;

Li, Xiaoyan ;

Wang, Jinliang ;

Ma, Junxun ;

Liu, Zhefeng ;

Huang, Di ;

Zheng, Xuan ;

Saito, Yuichi ;

Ichiki, Yoshinobu ;

Hu, Yi .

TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (03) :1397-+

[7] Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy [J].

Cortellini, Alessio ;

Di Maio, Massimo ;

Nigro, Olga ;

Leonetti, Alessandro ;

Cortinovis, Diego L. ;

Aerts, Joachim G. J., V ;

Guaitoli, Giorgia ;

Barbieri, Fausto ;

Giusti, Raffaele ;

Ferrara, Miriam G. ;

Bria, Emilio ;

D'Argento, Ettore ;

Grossi, Francesco ;

Rijavec, Erika ;

Guida, Annalisa ;

Berardi, Rossana ;

Torniai, Mariangela ;

Sforza, Vincenzo ;

Genova, Carlo ;

Mazzoni, Francesca ;

Garassino, Marina Chiara ;

De Toma, Alessandro ;

Signorelli, Diego ;

Gelibter, Alain ;

Siringo, Marco ;

Marchetti, Paolo ;

Macerelli, Marianna ;

Rastelli, Francesca ;

Chiari, Rita ;

Rocco, Danilo ;

Della Gravara, Luigi ;

Inno, Alessandro ;

Michele, De Tursi ;

Grassadonia, Antonino ;

Di Marino, Pietro ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Filetti, Marco ;

Santini, Daniele ;

Citarella, Fabrizio ;

Russano, Marco ;

Cantini, Luca ;

Tuzi, Alessandro ;

Bordi, Paola ;

Minuti, Gabriele ;

Landi, Lorenza ;

Ricciardi, Serena ;

Migliorino, Maria R. ;

Passiglia, Francesco ;

Bironzo, Paolo .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (04)

[8] Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) [J].

De Giglio, Andrea ;

Mezquita, Laura ;

Auclin, Edouard ;

Blanc-Durand, Felix ;

Riudavets, Mariona ;

Caramella, Caroline ;

Martinez, Gala ;

Benitez, Jose Carlos ;

Martin-Romano, Patricia ;

El-Amarti, Lamiae ;

Hendriks, Lizza ;

Ferrara, Roberto ;

Naltet, Charles ;

Lavaud, Pernelle ;

Gazzah, Anas ;

Adam, Julien ;

Planchard, David ;

Chaput, Nathalie ;

Besse, Benjamin .

CANCERS, 2020, 12 (10) :1-11

[9] Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study [J].

Egami, Saeka ;

Kawazoe, Hitoshi ;

Hashimoto, Hironobu ;

Uozumi, Ryuji ;

Arami, Toko ;

Sakiyama, Naomi ;

Ohe, Yuichiro ;

Nakada, Hideo ;

Aomori, Tohru ;

Ikemura, Shinnosuke ;

Fukunaga, Koichi ;

Yamaguchi, Masakazu ;

Nakamura, Tomonori .

FRONTIERS IN ONCOLOGY, 2021, 11

[10] Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study [J].

Egami, Saeka ;

Kawazoe, Hitoshi ;

Hashimoto, Hironobu ;

Uozumi, Ryuji ;

Arami, Toko ;

Sakiyama, Naomi ;

Ohe, Yuichiro ;

Nakada, Hideo ;

Aomori, Tohru ;

Ikemura, Shinnosuke ;

Fukunaga, Koichi ;

Yamaguchi, Masakazu ;

Nakamura, Tomonori .

JOURNAL OF CANCER, 2021, 12 (07) :2105-2112

← 1 2 3 4 →